Comparison · NCT02785952-sae
Nivolumab + Ipilimumab vs Nivolumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nivolumab + Ipilimumab vs Nivolumab: serious adverse events. Trial comparisons, record NCT02785952-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02785952-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.629 | 0.541 | 0.709 | wilson | |
| Risk in group 2 | 0.472 | 0.386 | 0.559 | wilson | |
| Risk difference, group 1 minus group 2 | 0.157 | 0.0334 | 0.275 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 1.06 | 1.68 | log | |
| Odds ratio, group 1 over group 2 | 1.9 | 1.14 | 3.16 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Nivolumab + Ipilimumab than on Nivolumab | 6.35 | 3.64 | 29.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nivolumab + Ipilimumab | Participants receive nivolumab on day 1 of each 14-day cycle and ipilimumab on day 1 of every third cycle beginning with cycle 1.~Nivolumab: Given IV Durvalumab: Given IV | 78 | 124 | EG000 |
| Group 2 | Nivolumab | Participants receive nivolumab on day 1 of each 14-day cycle.~Nivolumab: Given IV. | 58 | 123 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Duration of treatment and follow up until death or 3 years post registration
Source ClinicalTrials.gov
Trial
- Title
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- NCT number
- NCT02785952
- Phases
- PHASE3
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Lead sponsor
- SWOG Cancer Research Network
- Results first posted
- 2022-01-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02785952?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02785952-sae